The 340B program was initiated in 1992 by the US Congress to allow participating hospitals to generate additional revenue by purchasing certain drugs used for outpatient care at an approximately 22% discount while charging payers the full price.1,2 The program was designed to support hospitals caring for uninsured patients and low-income patients with Medicare and Medicaid coverage, allowing the hospitals to reach “more eligible patients” and provide “more comprehensive services.”2(p3) Although the 340B program was initially targeted to a select group of hospitals, participation has swelled, owing to expanded eligibility in 2004 and 2010 and the program’s popularity.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Nikpay S, Buntin M, Conti RM. Diversity of Participants in the 340B Drug Pricing Program for US Hospitals. JAMA Intern Med. 2018;178(8):1124–1127. doi:10.1001/jamainternmed.2018.2015
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: